Biotechnology There were two pieces of good news for US health care giant Johnson & Johnson (NYSE: JNJ) subsidiaries yesterday. First, the US Food and Drug Administration has approved Janssen Pharmaceuticals' supplemental New Drug Application (sNDA) for Nucynta ER (tapentadol) extended-release tablets, an oral analgesic taken twice daily, for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. 30 August 2012